West Pharmaceutical Services Inc (WST) Valuation

Based on the GoodMoat Investment Framework, the valuation assessment for West Pharmaceutical Services is unfavourable. The primary tool is the Discounted Cash Flow (DCF) model, which yields a GoodMoat Target of $166.89. The current price of $241.4 is 45% above this fair value estimate, resulting in a negative margin of safety. According to the framework's bands, a margin of safety of less than 10% is considered unfavourable; a negative value clearly fails this test. The forward P/E of 35.2 is elevated, especially when contextualized against the company's 7.5% year-over-year revenue growth. This suggests the market is pricing in significant future expectations, leaving little room for error. The free cash flow yield of 2.7% translates to a high P/FCF multiple of approximately 37x, which is not favourable for a value investor seeking a margin of safety. While the company demonstrates quality metrics like a strong ROE of 15.5% and a healthy balance sheet with low debt, the valuation multiples are stretched. For a value investor, the price does not provide the necessary discount to intrinsic value required for a favourable assessment. Analysis based on data as of 2024-05-15.